Related Experiment Video
Updated: Aug 9, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.3K
Glycosides as Potential Medicinal Components for Ulcerative Colitis: A Review
Yating Niu1, Jun Zhang2, Dianhua Shi2
1School of Basic Medical Science, Ningxia Medical University, Yinchuan 750004, China.
Molecules (Basel, Switzerland)
|July 14, 2023
Summary
Glycosides show promise in treating ulcerative colitis (UC) by reducing inflammation and oxidative stress. Further research into these natural compounds could lead to safer, more effective UC therapies.
Area of Science:
- Gastroenterology
- Pharmacology
- Natural Product Chemistry
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease with unclear etiology, characterized by abdominal pain, diarrhea, and bloody stools.
- Current treatments like aminosalicylates, glucocorticoids, and immunosuppressants have limitations, including side effects and recurrence, highlighting the need for novel therapies.
- Medicinal plants offer a diverse source of natural compounds for drug development, with glycosides emerging as potential therapeutic agents.
Purpose of the Study:
- To review the epidemiology and current treatments for ulcerative colitis (UC).
- To explore the protective and therapeutic potential of glycosides in managing UC.
- To elucidate the mechanisms of action of glycosides for UC treatment and guide preclinical research.
Main Methods:
- Literature review of UC epidemiology and existing drug therapies.
- Analysis of scientific evidence on the role of glycosides in UC.
- Review of proposed mechanisms underlying glycoside action in UC.
Main Results:
- Glycosides demonstrate potential in mitigating UC by modulating inflammatory and immune responses.
- Evidence suggests glycosides can inhibit oxidative stress, a key factor in UC pathogenesis.
- Glycosides may regulate signal transduction pathways involved in UC development.
Conclusions:
- Glycosides represent a promising class of natural compounds for developing new UC treatments.
- The anti-inflammatory, antioxidant, and immunomodulatory effects of glycosides provide a strong basis for their therapeutic application in UC.
- Further preclinical studies are warranted to validate the efficacy and safety of glycosides for UC prevention and treatment.
Related Concept Videos
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...